1-(4-氯丁基)吲哚 | 61205-54-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-(4-氯丁基)吲哚
• 英文名称: 1-(4-chlorobutyl)-1H-indole
• 英文别名: 1-(4-Chlorobutyl)indole；N-(4-chlorobutyl)indole
• CAS: 61205-54-7
• 化学式: C₁₂H₁₄ClN
• 分子量: 207.703
• InChiKey: QSJGZIIKWAHAFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-(4-氯丁基)吲哚 在 sodium iodide 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以66%的产率得到1-(4-iodobutyl)-1H-indole
  参考文献：
  名称：

  钯催化的成环芳族 C–H 烷基化与未活化的烷基卤化物

  摘要：

  描述了使用未活化的烷基卤化物和各种芳烃和杂芳烃的催化 CH 烷基化。这种成环过程适用于各种未活化的伯和仲烷基卤化物，包括具有 β-氢的那些。与芳香系统的标准极性或自由基环化相比，不需要底物的电子活化。温和的催化反应条件具有高度的官能团耐受性，有助于获得各种合成和医学上重要的碳环和杂环系统。

  DOI：

  10.1021/jacs.5b01365
• 作为产物：
  描述：

  1-phenylspiro[2a,7b-dihydroazeto[3,2-b]indol-3-ium-3,1'-azolidin-1-ium]-2-one;chloride 以90%的产率得到
  参考文献：
  名称：

  BENTLEY R. L.; SUSCHITZKY H., J. CHEM. SOC. PERKIN TRANS., 1976, PART 1, NO 16, 1725-1734

  摘要：

  DOI：

文献信息

• Nickel-catalyzed C–H alkylation of indoles with unactivated alkyl chlorides: evidence of a Ni(<scp>i</scp>)/Ni(<scp>iii</scp>) pathway
  作者：Dilip K. Pandey、Shidheshwar B. Ankade、Abad Ali、C. P. Vinod、Benudhar Punji

  DOI：10.1039/c9sc01446b

  日期：——

  described which demonstrates a high level of chemo and regioselectivity. The reaction tolerates numerous functionalities, such as halide, alkenyl, alkynyl, ether, thioether, furanyl, pyrrolyl, indolyl and carbazolyl groups including acyclic and cyclic alkyls under the reaction conditions. Mechanistic investigation highlights that the alkylation proceeds through a single-electron transfer (SET) process

  描述了一种温和有效的镍催化方法，用于将未活化的伯烷基氯和仲烷基氯与吲哚和吡咯的 CH 键偶联，该方法表现出高水平的化学和区域选择性。该反应在反应条件下耐受多种官能团，例如卤化物、烯基、炔基、醚、硫醚、呋喃基、吡咯基、吲哚基和咔唑基，包括无环和环状烷基。机理研究强调烷基化通过单电子转移 (SET) 过程进行，并以 Ni(i) 物质为活性催化剂。总体而言，烷基化遵循 Ni(i)/Ni(iii) 途径，涉及烷基氯的影响速率的两步单电子氧化加成。
• BENZISOXAZOLE PIPERIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE DERIVATIVES AND THEIR USE
  申请人：Li Jianqi

  公开号：US20110306638A1

  公开（公告）日：2011-12-15

  The invention relates to a benzisoxazolyl piperidine derivative having the following general formula, a salt or a hydrate thereof, wherein R, X, Y, R′ and T are defined as in the specification. Such compounds have serotonin system modulating effects such as antagonizing effect on 5-HT 2A and inhibitory effect on 5-HT reuptake. The compounds have good analgesic and sedative activities with mild toxic and side effects. The invention also relates to a composition comprising said derivative and the use thereof.

  本发明涉及一种苯并异噁唑基哌啶衍生物，其具有以下通式，其盐或水合物，其中R，X，Y，R'和T在规范中定义。这样的化合物具有调节血清素系统的作用，例如对5-HT2A的拮抗作用和对5-HT再摄取的抑制作用。这些化合物具有良好的镇痛和镇静活性，毒性和副作用较轻。本发明还涉及包含该衍生物的组合物及其使用。
• Tetrahydropyridine-(or 4-hydroxypiperidine) alkylazoles
  申请人：Laboratorios Del Dr. Esteve, S.A.

  公开号：US05731331A1

  公开（公告）日：1998-03-24

  The present invention relates to the compounds of general formula ##STR1## used as medicaments possessing therapeutic activity for the treatment of anxiety, psychosis, epilepsy, convulsion, motoricity problems, amnesia, cerebrovascular diseases or senile dementia.

  本发明涉及一般式为##STR1##的化合物，作为药物具有治疗焦虑、精神病、癫痫、惊厥、运动问题、遗忘症、脑血管疾病或老年痴呆症的治疗活性。
• New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4
  作者：Dario P. Anobile、Mauro Niso、Adrian Puerta、Stephanie M. Fraga Rodrigues、Francesca S. Abatematteo、Amir Avan、Carmen Abate、Chiara Riganti、Elisa Giovannetti

  DOI：10.3390/molecules27051682

  日期：——

  A new sigma-2 (σ2) receptor ligand (FA4) was efficiently synthesized and evaluated for cytotoxic, proapoptotic, and antimigratory activity on pancreatic ductal adenocarcinoma (PDAC) primary cell cultures, which restrained the aggressive and chemoresistant behavior of PDAC. This compound showed relevant antiproliferative activity with half maximal inhibitory concentration (IC50) values ranging from 0.701 to 0.825 μM. The cytotoxic activity was associated with induction of apoptosis, resulting in apoptotic indexes higher than those observed after exposure to a clinically relevant concentration of the gemcitabine, the first-line drug used against PDAC. Interestingly, FA4 was also able to significantly inhibit the migration rate of both PDAC-1 and PDAC-2 cells in the scratch wound-healing assay. In conclusion, our results support further studies to improve the library of thiosemicarbazones targeting the σ-2 receptor for a deeper understanding of the relationship between the biological activity of these compounds and the development of more efficient anticancer compounds against PDAC.

  一种新的sigma-2 (σ2) 受体配体(FA4)被高效地合成并在胰管腺癌(PDAC)原代细胞培养中评估其细胞毒性、促凋亡和抗迁移活性，该化合物抑制了PDAC的侵袭性和化疗耐药行为。该化合物表现出显著的抗增殖活性，半数抑制浓度(IC50)值在0.701至0.825 μM之间。细胞毒性活性与诱导凋亡相关，导致凋亡指数高于暴露于临床相关浓度的首选药物吉西他滨后观察到的指数。有趣的是，FA4还能显著抑制PDAC-1和PDAC-2细胞在划痕愈合实验中的迁移速率。总之，我们的结果支持进一步研究以改进靶向σ-2受体的硫脲类化合物库，以更深入地了解这些化合物的生物活性与更有效的PDAC抗癌化合物的开发之间的关系。
• Substituted anilinic piperidines as MCH selective antagonists
  申请人：Marzabadi R. Mohammad

  公开号：US20070043080A1

  公开（公告）日：2007-02-22

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

  本发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供了一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供了一种由本发明化合物的治疗有效量和药学上可接受的载体组成的药物组合物。本发明还提供了一种制备药物组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。